Team
LEADERSHIP TEAM
Stuart Collinson, PhD
Chairman and Chief Executive Officer


Dr. Collinson founded Tioga Pharmaceuticals with an initial investment from Forward Ventures (a life science venture capital firm), where he is also a partner.

Previously he was Chairman, Chief Executive Officer and President of Aurora Biosciences (acquired by Vertex Pharmaceuticals). Before Aurora, Dr. Collinson was Chief Executive Officer of Andaris Limited (acquired by Quadrant, now part of Perrigo). He held senior management positions at GlaxoWellcome (now GlaxoSmithKline) and Baxter International, and was a consultant with The Boston Consulting Group.

Dr. Collinson received an MBA from Harvard Business School and a PhD in Physical Chemistry from the University of Oxford.


Sophie Visonneau, PhD
Chief Operating Officer


Dr. Visonneau worked in Academic Research and the Pharmaceutical Industry for the last 20 years and brings experience in an array of therapeutic areas across the spectrum of R&D functions. Prior to joining Tioga, Dr. Visonneau held leadership positions at The Wistar Institute, SmithKline Beecham/GlaxoSmithKline, Immunomedics, Amgen, Biogen Idec, and more recently Shire. In these roles, she contributed to several IND submissions and helped design, conduct and analyze multiple Phase I-IV clinical trials, which resulted in several NDA/BLA submissions, approved marketed products, and indication extensions. In the last 10 years, Dr. Visonneau has diagnosed the gaps and needs of Clinical Operations organizations, building and implementing successful and efficient groups with accountability for the company’s R&D therapeutic portfolio at the global level. Dr. Visonneau was also involved in several successful partnership activities, including leading companies’ integrations and mergers, performing due diligence and evaluating business development opportunities.

Dr. Visonneau is the author of over 60 peer-reviewed publications, book chapters, and abstracts. Prior to joining the Pharmaceutical Industry, Dr. Visonneau received her PhD (Immunobiotechnology) from the Pierre and Marie Curie University of Sciences in Paris, France.


Dawn McGuire, MD FAAN
Chief Medical Officer (Consultant)


Dr. McGuire is a board-certified neurologist and Fellow of the American Academy of Neurology, and serves on the faculty of the Neuroscience Institute of the Morehouse School of Medicine. Dr. McGuire was the Chief Medical Officer for Acologix, heading the investigation of a kappa-opioid agonist in uremic pruritus. She has led development teams resulting in FDA approvals for therapeutics across three divisions of the FDA. Dr. McGuire holds a BA with High Honors from Princeton University and an MD from Columbia University College of Physicians & Surgeons. Her residency at University of California San Francisco was followed by a National Institutes of Health post-doctoral fellowship in clinical trial design and experimental therapeutics.


Raúl Collazo, PhD
Scientific and Medical Affairs Consultant


Dr. Collazo has worked as a Neurophysiologist in private practice and in the Pharmaceutical Industry for 20+ years. He has experience in a wide spectrum of therapeutic areas as a Medical Affairs and Compliance expert focusing on the creation and maturity of Medical Affairs teams, corporate communications, compliance strategies, and plans and tactics to support pre-market awareness, product launches, and in-line products. He has experience in global pharmaceutical companies and entrepreneurial biotech companies, holding positions of increasing leadership roles at Ortho-McNeil/J&J, Elán Pharmaceuticals, Neurocrine Biosciences, Orexigen Therapeutics, and Santarus. He has also consulted for numerous biotech firms in a consultancy leadership role.

Dr. Collazo is the author of over 40 peer-reviewed publications, book chapters, and abstracts. As an NIMH and McDonnell-Pew Fellow, Dr. Collazo received his PhD (Neuroscience) from the University of Oregon and completed a post-doctoral fellowship at the University of California, San Diego.


BOARD OF DIRECTORS
Stuart Collinson, PhD
Dr. Collinson founded Tioga Pharmaceuticals with an initial investment from Forward Ventures (a life science venture capital firm), where he is also a partner.

Previously he was Chairman, Chief Executive Officer and President of Aurora Biosciences (acquired by Vertex Pharmaceuticals). Before Aurora, Dr. Collinson was Chief Executive Officer of Andaris Limited (acquired by Quadrant, now part of Perrigo). He held senior management positions at GlaxoWellcome (now GlaxoSmithKline) and Baxter International, and was a consultant with The Boston Consulting Group.

Dr. Collinson received an MBA from Harvard Business School and a PhD in Physical Chemistry from the University of Oxford.


Arno Hartmann, PhD
Dr. Hartmann is the Head of the Corporate Patent Department for Merck KGaA. Dr. Hartmann joined Merck KGaA in 1990 and worked in the Licensing Department as well as the Business Development Unit before becoming the Head of Patent Pharmaceuticals in 2000.

Dr. Hartmann received a degree in chemistry from the University of Giessen, Germany in 1987 and earned a PhD in chemistry from the same institution in 1990. An expert in patent law, Dr. Hartmann has lectured extensively on due diligence, patent strategy, licensing and exploitation of IP. In addition, Dr. Hartmann is a core member of Merck KGaA’s Strategic Innovation Process, a project that seeks to take products that are not part of Merck’s core business and bring them into start-up companies financed by venture capital.


James Niedel, MD PhD
Dr. Niedel is a Managing Director of New Leaf Venture Partners, a firm that invests in life science companies.

Prior to joining the venture industry in 2002, Dr. Niedel was Chief Science and Technology Officer for GlaxoSmithKline and from 1995 to 2001 he was a member of the board of directors of Glaxo Wellcome plc with responsibility for Global Research and Development, Information Technology and Product Strategy. From 1988 to 1995 he was Vice President Research and Senior Vice President Research & Development for the US subsidiary of Glaxo.

Before joining the pharmaceutical industry, Dr. Niedel was Professor of Medicine and Chief of the division of Clinical Pharmacology at Duke Medical School, where he had completed an Internal Medicine residency and a Hematology-Oncology fellowship. He received the MD and PhD (Biochemistry) degrees from the University of Miami, was a Searle Scholar, and is a Fellow of the Royal College of Physicians (London).


Martin Muenchbach, PhD
Dr. Muenchbach is a Partner at BB Biotech Ventures. Previously, he was Partner at BioMedinvest and Investment Advisor at HBM Partners. At BioMedinvest, he led several of the firm's investments, and served on the board of portfolio companies. Before the merger of HBM Bioventures and NMT New Medical Technologies, he was Investment Manager at NMT, where he was focusing on international private equity investments in biopharmaceutical and biotechnological companies. Before NMT, Dr. Muenchbach gained experience in strategic marketing at Sanofi-Synthelabo.

Dr. Muenchbach holds a PhD in Protein Chemistry, a MSc in biochemistry and a Master in Economics from the Swiss Federal Institute of Technology (ETH), Zurich.


Jason Brown, PhD
Dr. Brown has been a Managing Director with C-Bridge Capital, a healthcare growth fund based in China, since October 2016. Previously, he was a Partner with Thomas, McNerney & Partners, where he served as a member of the investment team from 2007-2016. Prior to joining Thomas, McNerney, Dr. Brown spend four years as an investment professional at Forward Ventures.

Previously, Dr. Brown conducted research in antimicrobial drug discovery and bacterial genomics as a postdoctoral fellow in Infectious Diseases at Johnson & Johnson Pharmaceutical Research and Development.

Dr. Brown earned a PhD in Biology at the University of California, San Diego, where he was a National Science Foundation Fellow, and a BS in Molecular Biology and Biochemistry from Purdue University.